Soliris MG denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for soliris mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Soliris (Eculizumab) for Quantity Limits

A quantity-limit denial means Aetna's coverage policy restricts Soliris (eculizumab) to a defined amount — a maximum number of vials, infusions, or a specific dosing interval per coverage period — and the prescribed quantity or frequency exceeds that limit. Because Soliris dosing is weight-based and varies by indication, quantity-limit denials can occur when a patient's weight, dosing phase (induction versus maintenance), or specific approved indication requires a quantity that differs from the plan's default limit.

This denial is frequently overturned when the prescriber documents that the prescribed quantity matches the FDA-approved dosing regimen for the patient's specific indication and weight.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Most plans allow 180 days from the denial notice.
• External review (ACA §2719): If the internal appeal is denied, independent external review is available. The window is approximately four months from final internal denial. Expedited review is available for urgent cases.

## Appeal Process and Timeline

1. Request the denial letter specifying the quantity limit applied and the quantity requested. 2. Have your prescriber document in writing that the prescribed quantity is consistent with the FDA-approved dosing in the current Soliris prescribing label for the patient's indication, body weight, and phase of therapy. 3. File the internal appeal with this documentation. 4. If denied internally, escalate to external review.

## Documentation to Gather

• FDA prescribing label: Reference the current Soliris prescribing information for the approved dosing schedule for the specific indication. Your prescriber should confirm — in the appeal letter — that the prescribed quantity aligns with that label. (Do not reproduce specific dose numbers in the appeal letter if uncertain; instead, have the prescriber state that the prescribed quantity is consistent with the label-specified regimen for this indication and this patient's weight.)
• Patient weight and clinical parameters: Current body weight and relevant clinical parameters that drive the dosing calculation, documented in the chart.
• Indication documentation: Records confirming the specific FDA-approved indication, since dosing schedules differ across indications.
• Phase of therapy documentation: If the patient is in the induction (loading) phase rather than the maintenance phase, document this explicitly, as induction dosing is typically higher frequency.
• Prescriber medical-necessity letter: A letter explaining the clinical rationale for the prescribed quantity and citing the FDA-approved label as the basis.

## Criteria-Mapping Structure

Obtain Aetna's quantity-limit policy for Soliris. For each quantity restriction, document how the prescribed quantity either falls within or, if it exceeds the limit, why a medical exception is warranted based on label-specified dosing for this patient's indication and weight. Provide the chart dates and clinical notes that support the calculation. A well-structured quantity-limit appeal demonstrates that the prescriber is following the FDA label, not exceeding it.